Opinion

Multicenter Real-World Study Shows Comparable Safety and Efficacy of Ide-Cel in Patients with Relapsed/Refractory Multiple Myeloma

By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health   A multicenter retrospective study, which…

2 years ago

FDA Approves Pemigatinib in Patients with Relapsed/Refractory Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Finally a Treatment Option for a Challenging Disease

By Dr. Abhishek A. Mangaonkar Mayo Clinic   The phase 2 FIGHT-203 trial (NCT#03011372) studied 28 patients with relapsed/refractory myeloid/lymphoid…

2 years ago